SOURCE: BioSculpture Technology, Inc.

BioSculpture Technology, Inc.

April 10, 2015 07:15 ET

CEO Robert L. Cucin, M.D. of BioSculpture Technology, Inc. to Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network"

Live Interview to Air April 11th 2015 Hosted by Michael Yorba, 1:30pm ET/10:30am PT/12:30pm CT

WEST PALM BEACH, FL--(Marketwired - Apr 10, 2015) - BioSculpture Technology, Inc., a commercial stage medical device manufacturer developing a patented and prototyped minimally invasive device for the endoscopic removal of visceral or "belly" fat as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus, announced today that Chief Executive Officer (CEO) Robert L. Cucin, M.D. will be interviewed live by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" Show. In this exclusive interview, Dr. Cucin will discuss how the company believes their method and device will save lives, improve life outcomes, and significantly reduce healthcare costs. U.S. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.

Date: April 11, 2015 
Start Time:  1:30pm ET | 10:30am PT | 12:30pm CT (U.S.)
Network: Clear Channel - iHeart
Station: DFW 1190AM
KFXR Show: The Trader's Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About BioSculpture Technology, Inc.
BioSculpture Technology, Inc. ("BST") is a commercial stage medical device manufacturer developing a patented and prototyped minimally invasive device for the endoscopic removal of visceral or "belly" fat as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus. We believe our method and device will save lives, improve life outcomes, and significantly reduce healthcare costs.

BST's Corporate Mission is to be the world leading manufacturer and developer of medical devices and procedures for handling adipose tissue targeting: the bariatric market; and the liposuction and body sculpting market; fat autograft and adipocyte-derived stem cell processing markets.

About CEO Robert L. Cucin, M.D.
Dr. Cucin is a practicing plastic surgeon in Manhattan affiliated with The Presbyterian - New York Hospital, and New York University Downtown Hospitals. He received his undergraduate training from Cornell University where he received his B.A. and graduated magna cum laude in chemistry and with distinction in all subjects. He was granted his M.D. from Cornell Medical School and did both his General Surgery and Plastic & Reconstructive Surgery residences at The New York Hospital - Cornell University Medical Center. He is board-certified in plastic surgery and legal medicine and has a teaching appointment at the Weill Cornell Medical School.

He received a Juris Doctorate from Fordham Law School and is duly admitted to the New York, New Jersey and D.C. Bars and the American Trial Lawyers Association. His original research has been the subject of numerous contributions to the medical literature and he has published books in the fields of both medicine and law. Dr. Cucin funded the Rocin Foundation for Plastic Surgical Research to support his academic research and employs his combined degrees and experience in heading a Biotechnology Analysis and Advisory Service to assist new and established companies in developing and either manufacturing or licensing their biomedical intellectual property and to perform due diligence for investors interested in providing the start-up funds for ventures based upon new technology. Concentrating in finance, Dr. Cucin obtained an M.B.A. from Columbia Business School and is a member of Mensa.

Twenty years ago Dr. Cucin set up Rocin Laboratories, Inc. as a Research and Development company to perfect biomedical dermatologicals and devices. That company now has an extensive international patent portfolio and it is from that portfolio that first Lipotome Sales, then the Surgeons Tools Division, and now the separate company BioSculpture Technology, Inc. was funded to concentrate on the further refinement, manufacture and worldwide distribution of the most advanced body contouring, tissue aspiration, collecting, and processing technology of that portfolio. It is the application of that technology to the treatment of obesity and Company's emphasis on its accelerated development which warrants this interview.

About Clear Channel
Clear Channel's Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.

About The Traders Network Show
For the past six years "The Traders Network Show" has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 6am - 7:30am and 2pm - 3pm CT, Monday-Friday. Host Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It's a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more... shift your thinking and join us as we deliver "tomorrow's ideas today" on iHeart Radio and Clear Channel's The Traders Network Show. To inquire about being a guest on this show please contact "1800pr" at www.1800PublicRelations.com.

Contact Information